ESMO E-Learning: Clinical Management of Hypertension Induced by Treatment with Angiogenesis Inhibitors

Learning Objectives

  • To understand the mechanisms of hypertension (HTN) induced by Angiogenesis inhibitors.
  • To be able to recognise the risk factors and the frequency of HTN induced by angiogenesis inhibitors.
  • To understand the key point of treatment of HTN induced by angiogenesis inhibitors.

After two years E-Learning modules are no longer considered current. There is therefore no CME test associated with this E-Learning module. However, please note that this has been reviewed and approved as still relevant to the current practice knowledge by the ESMO E-Learning and Continuing Medical Education Working Group (ECWG) in 2014.

Jean-Philippe Spano
Jean-Philippe Spano
Read more
Thibault De La Motte Rouge
Thibault de La Motte Rouge
Read more

This presentation details the clinical management of hypertension as induced by treatment with Angiogenesis inhibitors, presented by experts, Prof. Jean-Philippe Spano and Dr. Thibault de La Motte Rouge.

Hypertension is one of the most frequent co-morbid conditions found in cancer patients and observed side-effects of systemic inhibition of vascular endothelial growth factor (VEGF) signalling. The advent of angiogenesis inhibition has revolutionised the treatment in oncology. The relationship between angiogenesis inhibitors and blood pressure has now been established and clinicians must recognise the growing evidence, that poorly controlled hypertension could lead to serious cardiovascular events in these patients. The incidence and severity of hypertension in cancer patients are dependent on the type of drugs, dose and schedule used, age of patients, as well as the presence of coexisting cardiac diseases. Proactive introduction or even prophylactic use of antihypertensive drugs can allow maintenance of therapy despite the onset of hypertension. This presentation will enable medical oncologists to understand the mechanisms and key points of treatment of hypertension induced by angiogenesis inhibitors. Knowledge of this clinical toxicity and/or therapeutic target or novel Biomarker of drug activity can aid clinicians in choosing the optimal and least toxic regimen suitable for an individual patient.

This E-Learning module was published in 2009 and expired in 2011.

Last update: 11 December 2009

The authors have reported no conflicts of interest.